Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azithromycin Feasibility in Sickle Cell Disease
NCT02960503Phase 2Withdrawn
- Sponsor
- Vanderbilt University
- Start
- Sep 2016
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in sickle cell disease (SCD) comparing Azithromycin with Placebo (2 arms). Primary endpoint: Acceptability of the trial (Recruitment, Retention, Adherence) at 6 months. Planned start Sep 2016; status: withdrawn.
02
Drugs
azithromycin
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT02960503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02960503.